Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 14/20 | 0.53 |
| ▸ | NPY1R | P25929 | 8/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.53 |
| ▸ | NPY2R | P49146 | 5/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534175 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31074734 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL31074830 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL29419494 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL7592903 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL7592909 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30838112 | 0.92 | NPY4R (0.53) | NPY4RNPY1RNPY5RNPY2RKEAP1 | |
| SCHEMBL29533534 | 0.90 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2RKISS1R | |
| SCHEMBL30998029 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30082669 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133839-A1 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) | TXP PHARMA GMBH (CH) | 2022-05-05 | — | — | US | disclosed |
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230568-B2 | Melanocortin 1 receptor ligands and methods of use | MC1R, MC3R, MC5R | NPY4R 40/4885NPY1R 14/4885NPY5R 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.